James E. Flynn - Director, * Director by Deputization, 10%+ Owner at Larimar Therapeutics, Inc.

Issuer-level insider activity

Role: Director, * Director by Deputization, 10%+ Owner
Issuer ticker: LRMR on Nasdaq
Entity type: Individual
Source filing history: Open source filing history

Past-year transaction volume for James E. Flynn in Larimar Therapeutics, Inc.

Buys

Open market

Shares: +5,000,000
Avg price: $5.00
Total value: +$25,000,000

Sells

Open market

Shares
Avg price
Total value

Net

Past year

Shares: +5,000,000
Share %: 100%
Total value: +$25,000,000

Reported holdings for James E. Flynn in Larimar Therapeutics, Inc.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 10,622,957
Estimated value: $53,114,785
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Private Design Fund IV, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 10,622,928
Estimated value: $53,114,640
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Private Design Fund III, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 8,153,107
Estimated value: $40,765,535
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Healthcare Innovations Fund, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Common Stock
Shares / value: 6,207,982
Estimated value: $31,039,910
Report date: 27 Feb 2026
Price: $5.00
Ownership: Through Deerfield Partners, L.P.

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 55,150
Estimated value
Report date: 19 May 2026
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount

Form 4 holding Director, * Director by Deputization, 10%+ Owner

Larimar Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 55,150
Estimated value
Report date: 19 May 2026
Price
Ownership: Through Deerfield Management Company, L.P.
Underlying class: Common Stock
Underlying amount

Transaction history for James E. Flynn in Larimar Therapeutics, Inc.

Sym	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares after	Date	Ownership

^* marks a reported price that did not pass the local price check.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .